Neos Therapeutics, Inc.
(NASDAQ : NEOS)

( )
NEOS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
1.68%17.522.0%$170.25m
SAGESAGE Therapeutics, Inc.
-1.79%137.299.5%$121.17m
PRGOPerrigo Co. Plc
-2.26%44.936.8%$100.11m
JAZZJazz Pharmaceuticals Plc
-0.32%128.662.2%$87.44m
GWPHGW Pharmaceuticals PLC Sponsored ADR
1.44%139.266.3%$78.73m
PTLAPortola Pharmaceuticals, Inc.
-3.77%25.537.7%$54.93m
ICPTIntercept Pharmaceuticals, Inc.
-2.22%110.9318.6%$52.57m
AXSMAxsome Therapeutics, Inc.
4.41%8.522.7%$46.12m
MNKMallinckrodt Plc
-3.15%19.9821.1%$40.05m
CTLTCatalent Inc
-0.62%35.392.4%$39.43m
ICLRICON Plc
-0.68%132.284.1%$38.89m
UTHRUnited Therapeutics Corporation
-1.60%113.9014.4%$34.98m
ENDPEndo International Plc
-4.23%9.298.9%$32.66m
HZNPHorizon Pharma plc
0.37%21.927.4%$26.48m
PCRXPacira Pharmaceuticals, Inc.
1.05%40.4610.6%$25.36m

Company Profile

Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30,1994 and is headquartered in Grand Prairie, TX.